{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:02Z","timestamp":1792269482044,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18835-9","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:09:24Z","timestamp":1759921764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeted design, synthesis, molecular dynamics, ADME and in \u2013vitro anticancer assessment of oxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids as potential BRAFV600E inhibitors"],"prefix":"10.1038","volume":"15","author":[{"given":"Ankit Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshwardhan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibullah","family":"Khalilullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Jaremko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-Hamid","family":"Emwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurica","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"18835_CR1","first-page":"59","volume":"2","author":"A Singh","year":"2023","unstructured":"Singh, A., Roghini, S. & Cancer Unraveling the complexities of uncontrolled growth and metastasis. Int. J. Pharm. Sci. 2, 59\u201373 (2023).","journal-title":"Int. J. Pharm. Sci."},{"key":"18835_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati, V., Mahapatra, D. K. & Bharti, S. K. PI3K\/Akt\/mTOR and ras\/raf\/mek\/erk signaling pathways inhibitors as anticancer agents: structural and Pharmacological perspectives. Eur. J. Med. Chem. 109, 314\u2013341 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"18835_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK\u2013RAS\u2013RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets. 16, 103\u2013119 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"key":"18835_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1535-6108(03)00189-2","volume":"4","author":"DA Tuveson","year":"2003","unstructured":"Tuveson, D. A., Weber, B. L. & Herlyn, M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 4, 95\u201398 (2003).","journal-title":"Cancer Cell."},{"key":"18835_CR5","doi-asserted-by":"publisher","first-page":"27819","DOI":"10.1021\/acsomega.3c00332","volume":"8","author":"AK Singh","year":"2023","unstructured":"Singh, A. K. et al. Challenges and opportunities in the crusade of BRAF inhibitors: from 2002 to 2022. ACS Omega. 8, 27819\u201327844 (2023).","journal-title":"ACS Omega"},{"key":"18835_CR6","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1039\/D3MD00145H","volume":"14","author":"T Ram","year":"2023","unstructured":"Ram, T. et al. MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. RSC Med. Chem. 14, 1837\u20131857 (2023).","journal-title":"RSC Med. Chem."},{"key":"18835_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/1871520622666220624164152","volume":"23","author":"AK Singh","year":"2023","unstructured":"Singh, A. K., Kumar, A., Thareja, S. & Kumar, P. Current insights into the role of BRAF inhibitors in treatment of melanoma. Anti-Cancer Agents Med. Chem. 23, 278\u2013297 (2023).","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"18835_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","volume":"30","author":"P Koelblinger","year":"2018","unstructured":"Koelblinger, P., Thuerigen, O. & Dummer, R. Development of Encorafenib for BRAF-mutated advanced melanoma. Curr. Opin. Oncol. 30, 125\u2013133 (2018).","journal-title":"Curr. Opin. Oncol."},{"key":"18835_CR9","doi-asserted-by":"crossref","unstructured":"Sun, J., Zager, J. S. & Eroglu, Z. Encorafenib\/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. OncoTarg Ther, 9081\u20139089 (2018).","DOI":"10.2147\/OTT.S171693"},{"key":"18835_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/14740338.2019.1607289","volume":"18","author":"KK Broman","year":"2019","unstructured":"Broman, K. K., Dossett, L. A., Sun, J., Eroglu, Z. & Zager, J. S. Update on BRAF and MEK Inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opin. Drug Saf. 18, 381\u2013392 (2019).","journal-title":"Expert Opin. Drug Saf."},{"key":"18835_CR11","doi-asserted-by":"publisher","first-page":"eaav8463","DOI":"10.1126\/sciadv.aav8463","volume":"5","author":"R R\u00f6ck","year":"2019","unstructured":"R\u00f6ck, R. et al. BRAF inhibitors promote intermediate BRAF (V600E) conformations and binary interactions with activated RAS. Sci. Adv. 5, eaav8463 (2019).","journal-title":"Sci. Adv."},{"key":"18835_CR12","doi-asserted-by":"publisher","first-page":"RP95334","DOI":"10.7554\/eLife.95334.4","volume":"13","author":"J Clayton","year":"2025","unstructured":"Clayton, J. et al. Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors. eLife 13, RP95334 (2025).","journal-title":"eLife"},{"key":"18835_CR13","doi-asserted-by":"publisher","first-page":"101740","DOI":"10.1016\/j.genrep.2023.101740","volume":"30","author":"AC Dcruz","year":"2023","unstructured":"Dcruz, A. C. et al. BRAF gene as a potential target to attenuate drug resistance and treat cancer. Gene Rep. 30, 101740 (2023).","journal-title":"Gene Rep."},{"key":"18835_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/DAD.0000000000000504","volume":"39","author":"JJ Lee","year":"2017","unstructured":"Lee, J. J., Kroshinsky, D. & Hoang, M. P. Cutaneous reactions to targeted therapy. Am. J. Dermatopathol. 39, 67\u201382 (2017).","journal-title":"Am. J. Dermatopathol."},{"key":"18835_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13543776.2019.1640680","volume":"29","author":"PF Wang","year":"2019","unstructured":"Wang, P. F., Qiu, H. Y. & Zhu, H. L. A patent review of BRAF inhibitors: 2013\u20132018. Expert Opin. Ther. Pat. 29, 595\u2013603 (2019).","journal-title":"Expert Opin. Ther. Pat."},{"key":"18835_CR16","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s11030-023-10699-3","volume":"28","author":"L Maji","year":"2024","unstructured":"Maji, L. et al. An updated literature on BRAF inhibitors (2018\u20132023). Mol. Divers. 28, 2689\u20132730 (2024).","journal-title":"Mol. Divers."},{"key":"18835_CR17","doi-asserted-by":"publisher","first-page":"e202200693","DOI":"10.1002\/cmdc.202200693","volume":"18","author":"V Pratap Reddy Gajulapalli","year":"2023","unstructured":"Pratap Reddy Gajulapalli, V. Development of Kinase-Centric Drugs: A Computational Perspective.. ChemMedChem18, e202200693 (2023).","journal-title":"ChemMedChem"},{"key":"18835_CR18","doi-asserted-by":"publisher","first-page":"105597","DOI":"10.1016\/j.bioorg.2022.105597","volume":"120","author":"PS Khan","year":"2022","unstructured":"Khan, P. S. et al. Recent advances in B-RAF inhibitors as anticancer agents. Bioorg. Chem. 120, 105597 (2022).","journal-title":"Bioorg. Chem."},{"key":"18835_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.bmcl.2007.11.038","volume":"18","author":"MK Parai","year":"2008","unstructured":"Parai, M. K., Panda, G., Srivastava, K. & Puri, S. K. Design, synthesis and antimalarial activity of benzene and isoquinoline sulfonamide derivatives. Bioorg. Med. Chem. Lett. 18, 776\u2013781 (2008).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"18835_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ejmech.2015.01.036","volume":"92","author":"MM Ghorab","year":"2015","unstructured":"Ghorab, M. M., Ragab, F. A., Heiba, H. I., El-Gazzar, M. G. & Zahran, S. S. Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives. Eur. J. Med. Chem. 92, 682\u2013692 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"18835_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"18835_CR22","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1021\/acschembio.6b00529","volume":"11","author":"M 22 Grasso","year":"2016","unstructured":"22 Grasso, M. et al. Chemically linked Vemurafenib inhibitors promote an inactive BRAFV600E conformation. ACS Chem. Biol. 11, 2876\u20132888 (2016).","journal-title":"ACS Chem. Biol."},{"key":"18835_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","volume":"234","author":"A \u0160ali","year":"1993","unstructured":"\u0160ali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of Spatial restraints. J. Mol. Biol. 234, 779\u2013815 (1993).","journal-title":"J. Mol. Biol."},{"key":"18835_CR24","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"18835_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-014-0037-3","volume":"6","author":"P Tosco","year":"2014","unstructured":"Tosco, P., Stiefl, N. & Landrum, G. Bringing the MMFF force field to the rdkit: implementation and validation. J. Cheminf. 6, 1\u20134 (2014).","journal-title":"J. Cheminf"},{"key":"18835_CR26","first-page":"4","volume":"1","author":"G Landrum","year":"2013","unstructured":"Landrum, G. Rdkit Documentation. Release 1, 4 (2013).","journal-title":"Release"},{"key":"18835_CR27","doi-asserted-by":"crossref","unstructured":"Bhattacharya, P. & Mandal, A. Identification of Amentoflavone as a potent SARS-CoV-2 Mpro inhibitor: a combination of computational studies and in vitro biological evaluation. J Biomol. Struct. Dyn 1\u201319 (2024).","DOI":"10.1080\/07391102.2024.2304676"},{"key":"18835_CR28","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated Docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"key":"18835_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/jcc.540110404","volume":"11","author":"BH Besler","year":"1990","unstructured":"Besler, B. H., Merz Jr, K. M. & Kollman, P. A. Atomic charges derived from semiempirical methods. J. Comput. Chem. 11, 431\u2013439 (1990).","journal-title":"J. Comput. Chem."},{"key":"18835_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","volume":"25","author":"J Wang","year":"2006","unstructured":"Wang, J., Wang, W., Kollman, P. A. & Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graphics Modell. 25, 247\u2013260 (2006).","journal-title":"J. Mol. Graphics Modell"},{"key":"18835_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157\u20131174 (2004).","journal-title":"J. Comput. Chem."},{"key":"18835_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","volume":"16","author":"C Tian","year":"2019","unstructured":"Tian, C. et al. ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J. Chem. Theory Comput. 16, 528\u2013552 (2019).","journal-title":"J. Chem. Theory Comput."},{"key":"18835_CR33","doi-asserted-by":"publisher","first-page":"W522","DOI":"10.1093\/nar\/gkm276","volume":"35","author":"TJ Dolinsky","year":"2007","unstructured":"Dolinsky, T. J. et al. PDB2PQR: expanding and upgrading automated Preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 35, W522\u2013W525 (2007).","journal-title":"Nucleic Acids Res."},{"key":"18835_CR34","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acs.jctc.9b00953","volume":"16","author":"MR Machado","year":"2020","unstructured":"Machado, M. R. & Pantano, S. Split the charge difference in two! A rule of thumb for adding proper amounts of ions in MD simulations. J. Chem. Theory Comput. 16, 1367\u20131372 (2020).","journal-title":"J. Chem. Theory Comput."},{"key":"18835_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0021-9991(83)90014-1","volume":"52","author":"HC Andersen","year":"1983","unstructured":"Andersen, H. C. & Rattle A velocity version of the shake algorithm for molecular dynamics calculations. J. Comput. Phy. 52, 24\u201334 (1983).","journal-title":"J. Comput. Phy"},{"key":"18835_CR36","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh ewald: an N log (N) method for Ewald sums in large systems. J. Chem. Phy. 98, 10089\u201310089 (1993).","journal-title":"J. Chem. Phy"},{"key":"18835_CR37","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1021\/jacs.9b11433","volume":"142","author":"VWD Cruzeiro","year":"2020","unstructured":"Cruzeiro, V. W. D., Feliciano, G. T. & Roitberg, A. E. Exploring coupled redox and pH processes with a force-field-based approach: applications to five different systems. J. Am. Chem. Soc. 142, 3823\u20133835 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"18835_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discovery. 10, 449\u2013461 (2015).","journal-title":"Expert Opin. Drug Discovery"},{"key":"18835_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/jcc.21372","volume":"31","author":"G Rastelli","year":"2010","unstructured":"Rastelli, G., Rio, A. D., Degliesposti, G. & Sgobba, M. Fast and accurate predictions of binding free energies using MM-PBSA and MM\u2010GBSA. J. Comput. Chem. 31, 797\u2013810 (2010).","journal-title":"J. Comput. Chem."},{"key":"18835_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejmech.2014.11.008","volume":"90","author":"Y Jiao","year":"2015","unstructured":"Jiao, Y. et al. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. Eur. J. Med. Chem. 90, 170\u2013183 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"18835_CR41","doi-asserted-by":"publisher","first-page":"1900053","DOI":"10.1002\/ardp.201900053","volume":"352","author":"P Pathak","year":"2019","unstructured":"Pathak, P. et al. Quinazoline based 1, 3, 5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: design, synthesis, docking, and QSAR study. Arch. Pharm. 352, 1900053 (2019).","journal-title":"Arch. Pharm."},{"key":"18835_CR42","doi-asserted-by":"publisher","first-page":"11812","DOI":"10.1080\/07391102.2023.2265486","volume":"42","author":"T Ram","year":"2024","unstructured":"Ram, T. et al. Design, one-pot synthesis, computational and biological evaluation of diaryl benzimidazole derivatives as MEK inhibitors. J. Biomol. Struct. Dyn. 42, 11812\u201311827 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"18835_CR43","doi-asserted-by":"publisher","first-page":"27355","DOI":"10.1039\/D2RA03624J","volume":"12","author":"AY Khormi","year":"2022","unstructured":"Khormi, A. Y. et al. Novel thiazole derivatives incorporating phenyl sulphonyl moiety as potent BRAFV600E kinase inhibitors targeting melanoma. RSC Adv. 12, 27355\u201327369 (2022).","journal-title":"RSC Adv."},{"key":"18835_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.32604\/or.2022.025187","volume":"29","author":"FH Tobeigei","year":"2022","unstructured":"Tobeigei, F. H. et al. Computational high-throughput screening and in vitro approaches identify CB-006-3; A novel PI3K-BRAFV600E dual targeted inhibitor against melanoma. Oncol. Res. 29, 305 (2022).","journal-title":"Oncol. Res."},{"key":"18835_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.tips.2014.12.001","volume":"36","author":"YC Chen","year":"2015","unstructured":"Chen, Y. C. Beware of docking! Trends Pharmacol. Sci. 36, 78\u201395 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"18835_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/17460441.2023.2275617","volume":"19","author":"TC Reese","year":"2024","unstructured":"Reese, T. C. et al. Evaluating physiochemical properties of FDA-approved orally administered drugs. Expert Opin. Drug Discovery. 19, 225\u2013238 (2024).","journal-title":"Expert Opin. Drug Discovery"},{"key":"18835_CR47","unstructured":"Khanna, V. & Ranganathan, S. In BMC Bioinf. 1\u201318 (Springer)."},{"key":"18835_CR48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/bs.apcsb.2015.09.004","volume":"102","author":"P Sneha","year":"2016","unstructured":"Sneha, P. & Doss, C. G. P. Molecular dynamics: new frontier in personalized medicine. Adv. Protein Chem. Struct. Biol. 102, 181\u2013224 (2016).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"18835_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1134\/S0026893308040195","volume":"42","author":"MY Lobanov","year":"2008","unstructured":"Lobanov, M. Y., Bogatyreva, N. & Galzitskaya, O. Radius of gyration as an indicator of protein structure compactness. Mol. Biol. 42, 623\u2013628 (2008).","journal-title":"Mol. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18835-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:04:06Z","timestamp":1759925046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18835-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18835"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18835-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35088"}}